- Company
- nAMD drug Vabysmo will likely be listed for reimb in Oct
- by Eo, Yun-Ho Sep 18, 2023 05:26am
- The macular degeneration treatment ‘Vabysmo’ is expected to be listed for reimbursement in October this year. According to industry sources, Roche Korea has completed drug pricing negotiations for its bispecific antibody Vabysmo (faricimab) with the National Health Insurance Service. Once it passes the Health Insurance Policy Review Com
- Company
- KRW 100 bil loxoprofen market suffers reimb cuts
- by Chon, Seung-Hyun Sep 18, 2023 05:26am
- Industry concerns are rising on the announcement of reimbursement cuts for the nonsteroidal anti-inflammatory drug ‘loxoprofen.’ The adequacy of its reimbursement as an antipyretic/analgesic for acute upper respiratory tract inflammation has not been recognized by the authorities in Korea, and its scope of prescriptions is set to be narrowed a
- Company
- nAMD tx Vabysmo can be prescribed at general hospitals
- by Eo, Yun-Ho Sep 15, 2023 05:33am
- Vabysmo, a treatment for macular degeneration, can be prescribed at general hospitals. According to related industries, Vabysmo, Roche Korea's first bispecific antibody treatment for eye diseases, passed the drug committee of medical institutions such as Konyang University Hospital, Kim Eye Clinic, Nune Eye Clinic, Inje University Busan P
- Company
- Gilead Sciences Korea appoints Jae-Yeon Choi as new head
- by Eo, Yun-Ho Sep 15, 2023 05:33am
- Gilead Sciences Korea announced it has appointed Jae-Yeon Choi as its new General Manager as of October this year. The position had remained vacant for the past 6 months. At Gilead Sciences Korea, the new GM Choi will oversee Gilead's business operations in Korea, and promote businesses in the fields of HIV, viral hepatitis, COVID-19, an
- Company
- Wellysis receives FDA approval for electrocardiograph
- by Nho, Byung Chul Sep 14, 2023 06:40am
- Access Bio (CEO Choi Young-ho), a global in vitro diagnostic company, announced on the 13th that Wellysis' patch-type electrocardiograph S-Patch Ex, with which it formed a strategic partnership last year, has received approval from the U.S. Food and Drug Administration (FDA). Access Bio previously made an investment by acquiring redeemable c
- Company
- Hanmi will focus on anti-obesity drugs... from GLP-1 to DTx
- by Kim, Jin-Gu Sep 14, 2023 06:37am
- Hanmi Science has pointed to obesity management as a future growth engine for the Hanmi Group. Hanmi Science plans to select 5 types of pipelines, including a new GLP-1 obesity treatment, and operate the project under the name, 'H.O.P (Hanmi Obesity Pipeline)'. The H.O.P project includes 5 types of treatment that include ▲'efpeglenatid
- Company
- SMA drugs Spinraza and Evrysdi complete pricing negotiations
- by Eo, Yun-Ho Sep 14, 2023 06:36am
- The spinal muscular atrophy (SMA) treatment ‘Evrysdi (risdiplam)’ finally passed the final hurdle to its reimbursement in Korea According to industry sources, both SMA treatments, Biogen Korea’s ‘Spinraza (nusinersen)’ and Roche Korea’s treatment ‘Evrysdi (risdiplam),’ reached a final agreement with the National Health Insurance S
- Company
- Obesity is a chronic disease
- by Kim, Jin-Gu Sep 12, 2023 05:37am
- “Currently, only obesity metabolic surgery is covered. The scope needs to be expanded to include obesity treatments, etc.” “Obesity is a chronic disease like high blood pressure and diabetes. We need to apply health insurance benefits from a treatment perspective, not from a beauty perspective.” Kim Gyeong-gon, vice president of the K
- Company
- Celltrion’s Remsima celebrates 10th year of export
- by Chon, Seung-Hyun Sep 12, 2023 05:37am
- Celltrion’s first biosimilar, ‘Remsima’, has marked its 10th anniversary in entering the overseas market. Together with its subcutaneous injection formulation Remsima SC, Remsima successfully settled in the European market and recorded total exports that exceeded KRW 6 trillion over the past 10 years. &8232; Celltrion Healthcare announced
- Company
- Entresto’s 2nd patent suit ruling postponed to November
- by Kim, Jin-Gu Sep 12, 2023 05:37am
- The rulings for the 2nd trial surrounding the chronic heart failure treatment ‘Entresto (sacubitril/valsartan)’ have been postponed to November 9. The drug has been posting&160;annual prescriptions of more than KRW 40 billion annually. &8232; According to industry sources on the 11th, the Patent Court of Korea 1st Division recently pos
